Retinopathy

Nephrology·MeSH: Kidney Diseases

Prevalence

2800.0 / 100K

Incidence

350.0 / 100K/yr

14 drugs in development·10 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
ABBV-RGX-314	REGENXBIO Inc. (RGNX)
AXPAXLI	OCULAR THERAPEUTIX, INC (OCUL)
m710	MOMENTA PHARMACEUTICALS INC (MNTA)
surabgene lomparvovec (sura-vec	REGENXBIO Inc. (RGNX)
tarcocimab	Kodiak Sciences Inc. (KOD)

Phase 2(1)

Drug	Company
emixustat	KUBOTA PHARMACEUTICAL HOLDINGS CO LTD (ACUC)

Phase 1(1)

Drug	Company
AKB-10108	Akebia Therapeutics, Inc. (AKBA)

Preclinical(1)

Drug	Company
acu-6151	KUBOTA PHARMACEUTICAL HOLDINGS CO LTD (ACUC)

Unknown(1)

Drug	Company
Lipanthyl™	ABBOTT LABORATORIES (ABT)

Phase 2/Phase 3(4)

Drug	Company
artificial tears	AbbVie Inc. (ABBV)
AT-003	Applied Therapeutics, Inc. (APLT)
sham	AbbVie Inc. (ABBV)
Surabgene Lomparvovec	AbbVie Inc. (ABBV)

Phase 4(1)

Drug	Company
faricimab	GH Research PLC (GHRS)

BioSniper tracks 14 drugs in development for Retinopathy across 10 companies.

There are 1 clinical trial targeting Retinopathy tracked by BioSniper.

The estimated prevalence of Retinopathy is approximately 2800.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.